An Open-label, Multicenter Phase 1 Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Maximum Tolerated Dose of VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Enitociclib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
- Focus Adverse reactions
- Sponsors Vincerx Pharma
- 14 Nov 2023 Status changed from recruiting to discontinued.
- 11 May 2023 According to Vincerx media release, the company anticipate dosing first patient in Phase 1b study of enitociclib in combination with an approved BTK inhibitor in patients with a high-risk chronic lymphocytic leukemia (CLL) in second quarter 2023.
- 28 Mar 2023 According to Vincerx media release, dosing first patient in 1b study is expected in Q2 of 2023.